Evidence map›Paper›PMID 36643977›Full record

ArticleFrontiers in nutrition2022

Naturally cultured high resistant starch rice improved postprandial glucose levels in patients with type 2 diabetes: A randomized, double-blinded, controlled trial.

Ling-Li Tan, Wei-Qian Duan, Meng-Xue Chen, Ying Mei, Xiao-Ya Qi, Yong Zhang

Open access · goldAbstract read
In one paragraph

Article in Frontiers in nutrition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ling-Li TanSchool of Public Health and Health Management, Chongqing Medical University, Chongqing, China.
Wei-Qian DuanSchool of Public Health and Health Management, Chongqing Medical University, Chongqing, China.
Meng-Xue ChenDepartment of Health Management, The Second Hospital Affiliated to Chongqing Medical University, Chongqing, China.
Ying MeiDepartment of Health Management, The Second Hospital Affiliated to Chongqing Medical University, Chongqing, China.
Xiao-Ya QiDepartment of Health Management, The Second Hospital Affiliated to Chongqing Medical University, Chongqing, China.
Yong ZhangSchool of Public Health and Health Management, Chongqing Medical University, Chongqing, China.
Chongqing Medical University · CNSecond Affiliated Hospital of Chongqing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To assess the effect of a novel naturally cultured rice with high resistant starch (RS) on postprandial glycemia in patients with type 2 diabetes compared to ordinary rice. Design: This study is a randomized, double-blinded controlled trial. Methods: Patients with type 2 diabetes were recruited, and postprandial glucose levels were measured at 5-time points after the ingestion of one of two types of cooked rice in random order. Paired Results: The increments of the postprandial blood glucose levels for high-RS rice were significantly lower than that for ordinary rice, i.e., 2.80 ± 1.38 mmol/L vs. 3.04 ± 1.50 mmol/L ( Conclusion: The novel high-RS rice as a staple food when substituting for widely consumed ordinary rice may provide potential health benefits by lowering blood glucose in patients with type 2 diabetes.

Indexed as

diabetespostprandial glucose levelrandomized controlled trial (RCT)resistant starch (RS)rice

Identifiers

PMID36643977
PMCPMC9833119
OpenAlexW4312070847

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.